After 14 years with the Group, and almost ten years as president and CEO,Magnus Groth has today informed the Board of Directors of Essity Aktiebolag (publ) that he has decided to step down as CEO and from the Board during 2025. A recruitment process for a successor will be initiated immediately. “As President and CEO […]
ProactiveMD, a leader in value-based, employer-sponsored healthcare, continues to disrupt the industry with aggressive growth, leveraging technology and strategic acquisitions to strengthen its national network. The company recently announced the acquisition of two major pathology groups, one in South Carolina and another in Alabama, marking a significant milestone in its mission to deliver high-quality, cost-effective
(NASDAQ:REGN), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wiping out about $9 billion of market value. Hagens Berman has opened an investigation into whether Regeneron may have misled investors about its marketing
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=124434&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=124433&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:ATRA) concerning possible violations of federal securities laws. Atara issued a press release on January 16, 2025, announcing receipt of "a Complete Response Letter (CRL) from
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who ownâ?¯Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stockâ?¯purchased prior to June 1, 2022. You are hereby notifiedâ?¯that Levi & Korsinsky, LLP has commenced anâ?¯investigationâ?¯into theâ?¯fairness
NEW YORK, NY / ACCESSWIRE / January 22, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who ownâ?¯Leafly Holdings Inc ("LFLY" or the "Company") (NASDAQ:LFLY) stockâ?¯purchased prior to January 28, 2022. You are hereby notifiedâ?¯that Levi & Korsinsky, LLP has commenced anâ?¯investigationâ?¯into theâ?¯fairness of the
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who ownâ?¯Starry Group Holdings Inc ("STRY" or the "Company") (:STRY) stockâ?¯purchased prior to March 12, 2022. You are hereby notifiedâ?¯that Levi & Korsinsky, LLP has commenced anâ?¯investigationâ?¯into
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who ownâ?¯Getaround, Inc. ("GETR" or the "Company") (NASDAQ:GETR) stockâ?¯purchased prior to December 2, 2022. You are hereby notifiedâ?¯that Levi & Korsinsky, LLP has commenced anâ?¯investigationâ?¯into theâ?¯fairness of